Effect of Immunization with a Common Recall Antigen on Viral Expression in Patients Infected with Human Immunodeficiency Virus Type 1

Stanley, Sharilyn K.; Ostrowski, Mario A.; Justement, Jesse S.; Gantt, Kira; Hedayati, Susan; Mannix, Margaret; Roche, Kim; Schwartzentruber, Douglas J.; Fox, Cecil H.; Fauci, Anthony S.
May 1996
New England Journal of Medicine;5/09/96, Vol. 334 Issue 19, p1222
Academic Journal
Background: Activation of the immune system is a normal response to antigenic stimulation, and such activation enhances the replication of human immunodeficiency virus type 1 (HIV-1). We studied the effect of immunization with a common recall antigen on viral expression in HIV-1–infected patients, on the ability to isolate virus, and on the susceptibility to HIV-1 infection of peripheral-blood mononuclear cells (PBMCs) from control subjects not infected with HIV-1. Methods: Thirteen HIV-1–infected patients and 10 uninfected adults were given a 0.5-ml booster dose of tetanus toxoid. Studies were performed to evaluate changes in the degree of plasma viremia, proviral burden, the ability to isolate HIV-1, and the susceptibility of PBMCs to acute infection in vitro. Two patients underwent sequential lymph-node biopsies for the assessment of viral burden in these tissues. Results: All 13 HIV-1–infected patients had transient increases in plasma viremia after immunization, and the proviral burden increased in 11. These changes did not correlate with the base-line CD4+ T-cell counts. The lymph-node tissue also had increases in the proviral burden and viral RNA after immunization. The virus was more easily isolated from PBMCs from nine of the patients after immunization than before immunization. Despite considerable variability in the results, PBMCs from 7 of the 10 normal subjects were more easily infected in vitro with HIV-1 after immunization than before immunization. Conclusions: Activation of the immune system by an ongoing antigen-specific immune response to an exogenous stimulus transiently increases the expression of HIV-1 and may enhance the susceptibility of uninfected subjects to HIV-1. (N Engl J Med 1996;334:1222-30.)


Related Articles

  • Activity of the Combination of Nelfinavir and Saquinavir Against Human Immunodeficiency Virus After Failure of Prior Protease Inhibitor Therapy. Kravcik, Stephen; Victor, Gary; Angel, Jonathan B.; Badley, Andrew D.; Cameron, D. William // Clinical Infectious Diseases;9/1/1999, Vol. 29 Issue 3, p702 

    Reports on the effectiveness of combining nelfinavir and saquinavir for the treatment of HIV infections. Details of a retrospective study on HIV-positive patients prescribed with nelfinavir and saquinavir; Effects of the drugs on the viral levels of the patients; Importance of treatment changes...

  • New Drug to Treat HIV/AIDS Approved. Nightingale, Stuart L. // JAMA: Journal of the American Medical Association;11/4/98, Vol. 280 Issue 17, p1472 

    Reports that the United States Food and Drug Administration (FDA) has approved efavirenz for use in combination with other antiretroviral agents in the treatment of HIV-1 infection. Background on resistant virus; Details on trials that were conducted; Side effects.

  • In brief.  // BMJ: British Medical Journal (International Edition);11/1/2003, Vol. 327 Issue 7422, p1006 

    Presents several news briefs related to medicine. Brokerage of a deal with four drug companies that will offer HIV therapy at reduced prices in some developing countries by the William J. Clinton Presidential Foundation; Death of four health workers after being injured by needles used on HIV...

  • Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Receiving Antiretroviral Therapy: Pathogenesis, Clinical Manifestations and Management. Dhasmana, Devesh J.; Dheda, Keertan; Ravn, Pernille; Wilkinson, Robert J.; Meintjes, Graeme // Drugs;2008, Vol. 68 Issue 2, p191 

    The use of antiretroviral therapy (ART) to treat HIV infection, by restoring CD4+ cell count and immune function, is associated with significant reductions in morbidity and mortality. Soon after ART initiation, there is a rapid phase of restoration of pathogen-specific immunity. In certain...

  • A Stochastic Model of Latently Infected Cell Reactivation and Viral Blip Generation in Treated HIV Patients. Conway, Jessica M.; Coombs, Daniel // PLoS Computational Biology;Apr2011, Vol. 7 Issue 4, p1 

    Motivated by viral persistence in HIV+ patients on long-term anti-retroviral treatment (ART), we present a stochastic model of HIV viral dynamics in the blood stream. We consider the hypothesis that the residual viremia in patients on ART can be explained principally by the activation of cells...

  • HIV heresy. Day, Michael // New Scientist;03/27/99, Vol. 161 Issue 2179, p26 

    Reports on the efforts of researchers to prove that HIV-infected people benefit from repeated breaks from their drug treatments. Suggested two week breaks from triple therapy; Possible boost in cytotoxic T lymphocyte (CTL) immune response; Report from Franco Lori on his test results for this...

  • Newer pneumococcal vaccine rouses immune response in adults with HIV.  // HIV Treatment ALERTS!;Sep2015, p35 

    The article discusses the impact of pneumococcal vaccine on the immune response of people with human immunodeficiency virus (HIV). Topics covered include the effect of pneumoniae on patients with HIV. Also mentioned are the invasion of the bacteria in the spinal fluid or blood of patients.

  • Introduction. Murphy, Robert L. // Clinical Infectious Diseases;6/1/2000 Supplement 2, Vol. 30, pS95 

    Discusses the challenges faced by clinicians in choosing an effective treatment regimen for patients with HIV infections. Decrease in the success rate and sustained treatment response to second-line therapies in clinics; Need to find effective treatment options that have favorable...

  • HIV Care and General Internal Medicine. Cofrancesco, Joseph; Wu, Albert W. // JGIM: Journal of General Internal Medicine;Sep2001, Vol. 16 Issue 9, p638 

    Discusses the key challenges of treating HIV-positive patients. Recognition of the disease; Access to data on HIV-infected persons; Quality of care for HIV patients.


Read the Article


Sign out of this library

Other Topics